Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02344589
Other study ID # SM-UG-14
Secondary ID
Status Completed
Phase Phase 4
First received January 16, 2015
Last updated January 27, 2015
Start date January 2015
Est. completion date January 2015

Study information

Verified date January 2015
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Health and Medicines Authority
Study type Interventional

Clinical Trial Summary

Our aim is to investigate which components of the quadriceps femoris muscle are affected following an ACB with different volumes (10, 20 and 30 ml) of 1% lignocaine evaluated by electromyography. Both a placebo treatment (20ml saline) and the femoral nerve block (20ml lignocaine 1%) as an active comparative will be used for model control. Further, we want to investigate the effect of volume on motor block. This will be evaluated by measuring the Maximum Voluntary Isometric Contraction (MVIC) of the quadriceps femoris muscle.


Description:

The ACB has a well-proven analgesic effect after TKA, but we do not know which nerves that are affected by the block. Aside being a motor nerve, the nerve to the vastus medialis of the quadriceps femoris muscle, contains the second largest sensory contribution from the femoral nerve. It is probable that some of the analgesic effect of the ACB arises from blocking this nerve.

Even though the ACB is mainly a sensory nerve block, a study in healthy volunteers showed a small decline by 8% in quadriceps muscle strength(10). It is speculated that the decline in muscle strength was caused by the spread of local anesthetic to the nerve supplying the vastus medialis of the quadriceps femoris muscle. Three out of eleven of the volunteers experienced an even larger decline of 25 % in quadriceps muscle strength. It has been argued that this decline likely was caused by a proximal spread of the local anesthetic to the femoral triangle thereby resulting in an affection of the femoral nerve. In this study, a volume of 30 ml of local anesthetic was used.

We do not know the optimal volume for the ACB and we find it relevant to investigate to what extent and which parts of the quadriceps muscle gets affected when different volumes of a local anesthetic are injected into the adductor canal. Selective affection of the different components of the femoral quadriceps muscle can be assessed by non-invasive EMG recordings. Further, the quadriceps femoris muscle strength will be evaluated by measuring the MVIC following the different volumes. The EMG recordings will be voluntary (vEMG) measured during MVIC and stimulated (sEMG). sEMG is measured during transcutaneous electrical stimulation of the femoral nerve.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age > 18 years old

- Subjects who gave their written informed consent to participating in the study after having fully understood the contents of the protocol and re-strictions.

- ASA 1

- Male

- BMI 18-30

- Physical exercise 1-3 hours/week

Exclusion Criteria:

- Subjects who cannot cooperate with the study.

- Subjects who cannot understand or speak Danish.

- Subjects with allergy to the medicines used in the study.

- Subjects suffering from alcohol and/or drug abuse - based on the investi-gator's opinion.

- Pathology or previous surgery or trauma to the lower limb.

- Intense exercise 24 h before the tests

- Intake of any analgesics 24 h prior to baseline measurements.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine
used for the active blocks
Saline
used for the placebo-block

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Ulrik Grevstad

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference between ACB-groups, one hour post-block, in amplitude of the rectified vEMG signal from the vastus medialis, expressed as percentage of the pre-block value. vEMG=voluntary electromyography one hour post-block No
Secondary • Difference between ACB-groups, one hour post-block, in amplitude of the rectified vEMG signal from the vastus lateralis, expressed as percentage of the pre-block value. vEMG=voluntary electromyography one hour post block No
Secondary • Difference between groups, one hour post-block, in MVIC expressed as percentage of the pre-block value MVIC=maximum voluntary isometric contraction. (Quadriceps femoris muscle) one hour post-block No
Secondary • Difference between ACB-groups, one hour post-block, in amplitude of the rectified sEMG signal from the vastus medialis, expressed as percentage of the pre-block value. sEMG= stimulated Electromyography one hour post-block No
Secondary • Difference between ACB-groups, one hour post-block, in amplitude of the rectified sEMG signal from the vastus lateralis, expressed as percentage of the pre-block value. sEMG= stimulated Electromyography one hour post-block No
Secondary • Association between volume and MVIC. MVIC expressed as a percentage of the pre-block value. one hour post-block No
Secondary Difference in proportions between ACB-groups having an affection of both the saphenous nerve and the vastus medialis (but no other components of the quadriceps femoris muscle), one hour post block evaluated by EMG For each subject a series of 5 voluntary EMG recordings during MVIC will be made to estab-lish the variability of the EMG recordings. This will be done prior to the blocks on each day resulting in 300 EMG recordings from the vastus medialis and 300 recordings from the vastus lateralis. From this variability we will establish a cut-off point (how large a decline in EMG amplitude is "synonymous" with affection of the nerve?). After the cut-off point has been established the EMG data will be presented in dichotomous form: affected/not affected one hour post-block No
See also
  Status Clinical Trial Phase
Recruiting NCT04226339 - Evaluation of Walking Analysis After a Total Knee Arthroplasty With Kinematic Alignment Versus Mechanical Alignment N/A
Completed NCT03276143 - FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty Phase 2
Completed NCT03308071 - Hypnosis for Symptom Management in Elective Orthopedic Surgery N/A
Recruiting NCT05100706 - Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty N/A
Completed NCT04090125 - Improving Physical Activity and Gait Symmetry After Total Knee Arthroplasty N/A
Recruiting NCT04564729 - Shared Decision Aid for Post-Total Knee Arthroplasty Opioid Prescribing N/A
Recruiting NCT03695640 - Effect of Magnesium Sulphate on Analgesia Following Knee Arthroplasty Phase 4
Recruiting NCT05877261 - Cementless Triathlon 5YR Follow-Up
Recruiting NCT05516381 - Evaluation of Navigation-Assisted TKA Using Mechanical vs. Restricted Kinematic Alignment N/A
Completed NCT04450485 - Surgical Approach in Fast Track Knee Arthroplasty N/A
Recruiting NCT06108063 - Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan Phase 1/Phase 2
Recruiting NCT06389435 - RObotic-assisted Versus Conventional Knee Endoprosthetic Techniques N/A
Completed NCT03898544 - Gait Kinematics After Primary Total Knee Arthroplasty (TKA) Versus Revision TKA
Completed NCT03492320 - Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty
Active, not recruiting NCT02445443 - LEGION Hinge Safety and Efficacy Study
Terminated NCT02830087 - Tourniquet Pressure in Primary Total Knee Arthroplasty N/A
Completed NCT02186587 - iTotal Pilot Study of ConforMIS Custom Total Knee Implant N/A
Completed NCT00711711 - Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery N/A
Active, not recruiting NCT05788757 - Optetrak Knee System Post Market Clinical Follow-Up
Completed NCT03703206 - The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA) Phase 3